| MIR155 |
|
microRNA 155
|
|
|
0.384 |
0.885 |
| IGH |
|
immunoglobulin heavy locus
|
|
|
0.473 |
0.654 |
| CDR3 |
|
Cerebellar degeneration-related autoantigen-3
|
|
|
0.472 |
0.808 |
| PVT1 |
|
Pvt1 oncogene
|
|
|
0.495 |
0.731 |
| MIR34B |
|
microRNA 34b
|
|
|
0.509 |
0.808 |
| LOC102723407 |
|
immunoglobulin heavy variable 4-38-2-like
|
|
|
0.514 |
0.769 |
| LOC102724971 |
|
putative V-set and immunoglobulin domain-containing-like protein IGHV4OR15-8
|
|
|
0.527 |
0.769 |
| IGHV3-69-1 |
|
immunoglobulin heavy variable 3-69-1 (pseudogene)
|
|
|
0.561 |
0.654 |
| IGHV3OR16-7 |
|
immunoglobulin heavy variable 3/OR16-7 (pseudogene)
|
|
|
0.566 |
0.654 |
| PCAT1 |
|
prostate cancer associated transcript 1
|
|
|
0.575 |
0.615 |
| MIR4435-2HG |
|
MIR4435-2 host gene
|
|
|
0.604 |
0.692 |
| TSBP1-AS1 |
|
TSBP1 and BTNL2 antisense RNA 1
|
|
|
0.638 |
0.692 |
| IGHG1 |
P01857
|
immunoglobulin heavy constant gamma 1 (G1m marker)
|
|
|
0.700 |
0.500 |
| DRAIC |
|
downregulated RNA in cancer, inhibitor of cell invasion and migration
|
|
|
0.736 |
0.423 |
| CASC19 |
|
cancer susceptibility 19
|
|
|
0.769 |
0.423 |
| IGHV3-21 |
A0A0B4J1V1
|
immunoglobulin heavy variable 3-21
|
|
|
0.780 |
0.192 |
| ACOXL-AS1 |
|
ACOXL antisense RNA 1
|
|
|
0.861 |
0.154 |
| DACT3-AS1 |
|
DACT3 antisense RNA 1
|
|
|
0.931 |
0.115 |
| ATM |
Q13315
|
ATM serine/threonine kinase
|
Kinase
|
5.6E-47 |
0.374 |
0.885 |
| ULK4 |
Q96C45
|
unc-51 like kinase 4
|
Kinase
|
4.4E-38 |
0.722 |
0.385 |
| FARP2 |
O94887
|
FERM, ARH/RhoGEF and pleckstrin domain protein 2
|
|
4.6E-36 |
0.678 |
0.615 |
| OAS3 |
Q9Y6K5
|
2'-5'-oligoadenylate synthetase 3
|
Enzyme
|
2.0E-33 |
0.608 |
0.615 |
| SLC28A1 |
O00337
|
solute carrier family 28 member 1
|
Transporter
|
5.7E-20 |
0.686 |
0.538 |
| MME |
P08473
|
membrane metalloendopeptidase
|
Enzyme
|
1.5E-18 |
0.407 |
0.808 |
| TSBP1 |
Q5SRN2
|
testis expressed basic protein 1
|
|
1.5E-16 |
0.638 |
0.692 |